Summary OrbusNeich is a medical device company that designs, develops, manufactures and markets medical devices for cardiovascular markets. It focuses on the development of cardiology devices for the treatment of vascular diseases. The company offers products that include bio-engineered stents, dual therapy stent, bare metal stents and balloons. OrbusNeich's bio engineered stent is a pro-healing stent that utilizes immobilized antibodies to capture circulating endothelial progenitor cells. The company also conducts several clinical programs. It markets its products through the channel of network distributors. The company has its presence in the Netherlands, China, Japan, Hong Kong, Malaysia and Korea, among others. OrbusNeich is headquartered in Hong Kong. This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company OrbusNeich - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons To Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 OrbusNeich Company Snapshot 5 OrbusNeich Company Overview 5 OrbusNeich Pipeline Products and Clinical Trials Overview 6 OrbusNeich - Pipeline Analysis Overview 8 Key Facts 8 OrbusNeich - Major Products and Services 9 OrbusNeich Pipeline Products by Development Stage 10 OrbusNeich Clinical Trials by Trial Status 12 OrbusNeich Pipeline Products Overview 14 Acute BRS 14 Acute BRS Product Overview 14 COMBO Dual Therapy Stent 15 COMBO Dual Therapy Stent Product Overview 15 COMBO Dual Therapy Stent Clinical Trial 16 COMBO Dual Therapy Stent - 38 mm 19 COMBO Dual Therapy Stent - 38 mm Product Overview 19 Cura Stent 20 Cura Stent Product Overview 20 ON-AVS Scaffold 21 ON-AVS Scaffold Product Overview 21 OrbusNeich - Key Competitors 22 OrbusNeich - Key Employees 23 OrbusNeich - Locations And Subsidiaries 24 Head Office 24 Other Locations & Subsidiaries 24 Recent Developments 25 OrbusNeich, Recent Developments 25 May 24, 2016: OrbusNeich Expands Portfolio To Include Scoreflex PTA balloon Catheter 25 May 24, 2016: OrbusNeich Introduces News JADE catheter to Treat Peripheral Disease 25 May 03, 2016: OrbusNeich Announces the Last Patient Enrollment in PhysicianInitiated Study to Evaluate the Potential for Shorter Dual Antiplatelet Therapy in ACS Patients 25 Feb 01, 2016: OrbusNeich highlights Sapphire II PRO at AsiaPCR/SingLIVE 2016 26 Feb 01, 2016: OrbusNeich showcases Scoreflex at AsiaPCR/SingLIVE 2016 27 Dec 17, 2015: OrbusNeich demonstrstes Scoreflex Coronary Dilatation Catheter at GulfPCR-GIM 2015 27 Dec 17, 2015: OrbusNeich demonstrates Sapphire II Coronary Dilatation Catheter at GulfPCR-GIM 2015 28 Oct 19, 2015: One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015 29 Jul 20, 2015: OrbusNeich Announces Enrollment of First Patient in China Recovery Study 29 Jun 04, 2015: COMBO Dual Therapy Stent demonstrates true tissue maturation with low clinical events rate out to 4 years at EuroPCR 2015 30 Appendix 32 Methodology 32 About GlobalData 32 Contact Us 32 Disclaimer 32
List of Tables
OrbusNeich Pipeline Products and Clinical Trials Overview 6 OrbusNeich Pipeline Products by Equipment Type 6 OrbusNeich Pipeline Products by Indication 7 OrbusNeich Clinical Trials by Trial Status 7 OrbusNeich, Key Facts 8 OrbusNeich, Major Products and Services 9 OrbusNeich Number of Pipeline Products by Development Stage 10 OrbusNeich Pipeline Products Summary by Development Stage 11 OrbusNeich Clinical Trials by Trial Status 12 OrbusNeich Clinical Trials Summary 13 Acute BRS - Product Status 14 Acute BRS - Product Description 14 COMBO Dual Therapy Stent - Product Status 15 COMBO Dual Therapy Stent - Product Description 15 COMBO Dual Therapy Stent - A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients with De Novo Stenotic Lesions of Native Coronary Artery: RECOVERY 16 COMBO Dual Therapy Stent - China Recovery Study of COMBO Dual Therapy Stent 16 COMBO Dual Therapy Stent - Japan-USA Harmonized Assessment by Randomized, Multi-center Study of Orbusneich's Combo Stent (Japan-USA HARMONEE): Assessment of a Novel DES Platform for Percutaneous Coronary Revascularization in Patients with Ischemic Coronary Disease and NSTEMI Acute Coronary Syndrome 17 COMBO Dual Therapy Stent - Multicenter, Prospective, Clinical Outcomes after Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio- Engineered Sirolimus Eluting Stent) Post Market Registry 17 COMBO Dual Therapy Stent - Multinational Abluminal Sirolimus Coated Bio-engineered Stent: The MASCOT Post Marketing Registry 18 COMBO Dual Therapy Stent - Prospective, Multi-centre, Randomized, Parallel Comparison to Evaluate the Safety and Efficacy of the Abluminal Sirolimus Coated Bio-engineered Stent (COMBO Stent) in Association with Short-term Single Antiplatelet Therapy in Patients with Coronary Artery Disease with an Indication for Chronic Oral Anticoagulant Therapy as Compared to a Guidelines-based Strategy 18 COMBO Dual Therapy Stent - 38 mm - Product Status 19 COMBO Dual Therapy Stent - 38 mm - Product Description 19 Cura Stent - Product Status 20 Cura Stent - Product Description 20 ON-AVS Scaffold - Product Status 21 ON-AVS Scaffold - Product Description 21 OrbusNeich, Key Employees 23 OrbusNeich, Other Locations 24 OrbusNeich, Subsidiaries 24
List of Figures
OrbusNeich Pipeline Products by Equipment Type 7 OrbusNeich Pipeline Products by Development Stage 10 OrbusNeich Clinical Trials by Trial Status 12
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global automotive collision repair market is expected to be valued at USD 196.97 billion by 2020, as per a new research report by Radiant Insights, Inc. The industry is expected to witness significant growth owing to increasing number of on-road vehiRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.